Skip to main content
  • Sign in
    Welcome !
    My account
    Logout

Candel Therapeutics, Inc. (CADL) Stock Forecast 2025 - AI Price Prediction & Analysis

Candel Therapeutics, Inc. (CADL) AI Stock Price Forecast & Investment Analysis

Candel Therapeutics, Inc. Stock Price Chart and Technical Analysis

Loading Candel Therapeutics, Inc. interactive price chart and technical analysis...

Candel Therapeutics, Inc. (CADL) - Comprehensive Stock Analysis & Investment Research

Deep dive into Candel Therapeutics, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Understanding Company Overview

What this section covers: Essential business information about Candel Therapeutics, Inc., including sector classification, industry positioning, and organizational structure.

How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.

For Candel Therapeutics, Inc.: Candel Therapeutics, Inc. operates in the Life Sciences sector, making it an emerging small-cap investment.

Candel Therapeutics, Inc. (Stock Symbol: CADL) is a leading company in the Life Sciences sector , specifically operating within the Biological Products, (No Diagnostic Substances) industry.

The organization employs approximately 88 professionals worldwide .

The company has established itself as an emerging investment opportunity with substantial growth potential.

Understanding Financial Performance

What these metrics mean: Key financial indicators showing Candel Therapeutics, Inc.'s revenue scale, profitability, market value, and shareholder returns.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Candel Therapeutics, Inc.: With $5M in annual revenue and -999.0% net margin, the company demonstrates developing profitability.

Annual Revenue: $5 million generating a -999.0% net profit margin .

Market Capitalization: $306 million - Classified as a small-cap investment offering high growth potential.

Return on Equity (ROE): -179.4% - Below-average shareholder return efficiency, indicating areas for operational improvement.

Understanding AI Stock Predictions

What these predictions mean: AI-powered forecasts for Candel Therapeutics, Inc. stock using machine learning algorithms trained on historical market data and technical indicators.

How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Spearman correlation coefficient shows the statistical relationship between predictions and actual outcomes.

For Candel Therapeutics, Inc.: Unlock premium access to view detailed AI predictions and price targets.

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Candel Therapeutics, Inc. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Understanding Market Position

What this analysis covers: Candel Therapeutics, Inc.'s competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.

How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.

For Candel Therapeutics, Inc.: Market positioning analysis based on available financial and operational metrics.

Candel Therapeutics, Inc. strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace, representing an emerging small-cap investment with substantial growth potential and market disruption capabilities .

Candel Therapeutics, Inc. (CADL) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Candel Therapeutics, Inc. stock analysis.

Loading Candel Therapeutics, Inc. comprehensive fundamental analysis and insider trading data...

Deep dive into Candel Therapeutics, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Candel Therapeutics, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Candel Therapeutics, Inc.: With a P/E ratio of -4.60, the market sees the stock as potentially undervalued.

P/E Ratio -4.60x
P/B Ratio 3.40x
Market Cap $306M
EPS $-1.74
Book Value/Share $1.64
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Candel Therapeutics, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Candel Therapeutics, Inc.: An ROE of -179.4% indicates room for improvement in shareholder value creation.

ROE -179.4%
ROA -47.6%
ROIC -107.6%
Operating Margin -712.5%
Net Margin -999.0%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Candel Therapeutics, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Candel Therapeutics, Inc.: A current ratio of 17.48 indicates strong liquidity.

Current Ratio 17.48x
Quick Ratio 17.23x
D/E Ratio 0.35x
Financial Leverage 1.59x
Interest Coverage -149.6x
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Candel Therapeutics, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Candel Therapeutics, Inc.: Free cash flow of $-26M indicates cash challenges that need attention.

Operating Cash Flow $-25M
Free Cash Flow $-26M
Capital Spending $-2M
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Candel Therapeutics, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Candel Therapeutics, Inc.:

Fixed Assets Turnover 0.0x
Understanding Financial Statement Data

What these metrics mean: Key figures from Candel Therapeutics, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Candel Therapeutics, Inc.: With annual revenue of $5M, Candel Therapeutics, Inc. represents a smaller but potentially high-growth operation.

Income Statement ($ Millions)
Total Revenue $5M
R&D Expense $22M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 94%
Cash & Short-term Investments 93%
Total Liabilities 37%
Short-term Debt 1%
Dividend & Shareholder Information
Shares Outstanding 55M
Growth Metrics (YoY)
EPS Growth -15.0%

Latest Candel Therapeutics, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Candel Therapeutics, Inc. (CADL) stock price and investment outlook.

📰 We are currently updating our news feed for Candel Therapeutics, Inc.. Check back soon for the latest market analysis and company updates.

Candel Therapeutics, Inc. Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Candel Therapeutics, Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
ABOS Unlock Forecast - 30 Days FREE Trial $123M -1.9x 1.1x
ABP Unlock Forecast - 30 Days FREE Trial $13M x 0.0x
ACLX Unlock Forecast - 30 Days FREE Trial $4845M -74.1x 12.4x
ACOG Unlock Forecast - 30 Days FREE Trial $110M x 3.5x
ADAP Unlock Forecast - 30 Days FREE Trial $318M -13.2x -11.8x
ADMA Unlock Forecast - 30 Days FREE Trial $3705M 17.3x 9.3x
ADPT Unlock Forecast - 30 Days FREE Trial $2558M -4.6x 14.2x
AGEN Unlock Forecast - 30 Days FREE Trial $116M -0.5x -0.5x
AIM Unlock Forecast - 30 Days FREE Trial $2M -0.5x -183.3x
AIMI Unlock Forecast - 30 Days FREE Trial $2M x x
ALEC Unlock Forecast - 30 Days FREE Trial $154M -1.2x 2.2x
ALGS Unlock Forecast - 30 Days FREE Trial $61M -19.2x 0.6x
ALLO Unlock Forecast - 30 Days FREE Trial $266M -1.4x 0.8x
AMGN Unlock Forecast - 30 Days FREE Trial $157184M 23.8x 21.2x
APGE Unlock Forecast - 30 Days FREE Trial $3262M -20.5x 4.3x
APTOF Unlock Forecast - 30 Days FREE Trial $4M x x
ARMP Unlock Forecast - 30 Days FREE Trial $123M -1.0x -1.6x
ARTV Unlock Forecast - 30 Days FREE Trial $132M x 0.9x
ATHA Unlock Forecast - 30 Days FREE Trial $143M -0.2x 4.5x
ATRA Unlock Forecast - 30 Days FREE Trial $103M 17.8x -1.1x
AURA Unlock Forecast - 30 Days FREE Trial $377M -4.9x 2.2x
AUTL Unlock Forecast - 30 Days FREE Trial $403M x 1.2x
AVXL Unlock Forecast - 30 Days FREE Trial $700M -17.3x 7.7x
BCLI Unlock Forecast - 30 Days FREE Trial $7M -4.9x -0.9x
BCRX Unlock Forecast - 30 Days FREE Trial $1534M -12.1x -4.0x
BDTX Unlock Forecast - 30 Days FREE Trial $228M 15.8x 1.7x
BEAM Unlock Forecast - 30 Days FREE Trial $2496M -12.6x 2.4x
BIIB Unlock Forecast - 30 Days FREE Trial $21963M 14.4x 1.5x
CABA Unlock Forecast - 30 Days FREE Trial $226M -1.6x 1.3x
CADL Unlock Forecast - 30 Days FREE Trial $306M -4.6x 3.4x
CCCC Unlock Forecast - 30 Days FREE Trial $174M -2.6x 1.0x
CDTX Unlock Forecast - 30 Days FREE Trial $2432M -1.0x 4.9x
CELZ Unlock Forecast - 30 Days FREE Trial $9M -3.4x 1.4x
CERO Unlock Forecast - 30 Days FREE Trial $1M x -196.2x
CGEM Unlock Forecast - 30 Days FREE Trial $447M -4.1x 0.9x
CGEN Unlock Forecast - 30 Days FREE Trial $176M x 3.5x
CGON Unlock Forecast - 30 Days FREE Trial $3276M x 4.9x
CGTX Unlock Forecast - 30 Days FREE Trial $113M -0.5x 16.1x
CHRS Unlock Forecast - 30 Days FREE Trial $192M 1.1x 1.6x
CLDI Unlock Forecast - 30 Days FREE Trial $5M -0.9x 2.6x
CMPX Unlock Forecast - 30 Days FREE Trial $519M -4.8x 5.6x
CRBU Unlock Forecast - 30 Days FREE Trial $216M -1.5x 1.3x
CRDF Unlock Forecast - 30 Days FREE Trial $148M -4.0x 2.5x
CRIS Unlock Forecast - 30 Days FREE Trial $16M -0.3x -2.9x
CRSP Unlock Forecast - 30 Days FREE Trial $5400M -12.1x 3.2x
CVM Unlock Forecast - 30 Days FREE Trial $47M -0.9x 6.7x
DBVT Unlock Forecast - 30 Days FREE Trial $1930M -3.3x 36.5x
DNA Unlock Forecast - 30 Days FREE Trial $687M -13.9x 0.4x
DNLI Unlock Forecast - 30 Days FREE Trial $2367M -8.7x 2.3x
DTIL Unlock Forecast - 30 Days FREE Trial $78M -2.2x 2.3x
EDIT Unlock Forecast - 30 Days FREE Trial $263M -0.8x 13.7x
ELUT Unlock Forecast - 30 Days FREE Trial $40M -1.4x -0.1x
ENGN Unlock Forecast - 30 Days FREE Trial $371M 3.7x 1.9x
ENTX Unlock Forecast - 30 Days FREE Trial $107M 8.5x 6.2x
ESLA Unlock Forecast - 30 Days FREE Trial $65M -3.1x -16.9x
EXEL Unlock Forecast - 30 Days FREE Trial $10519M 17.1x 5.2x
EXOZ Unlock Forecast - 30 Days FREE Trial $106M x 14.7x
FATE Unlock Forecast - 30 Days FREE Trial $169M -1.3x 0.7x
FDMT Unlock Forecast - 30 Days FREE Trial $527M -3.0x 1.3x
FENC Unlock Forecast - 30 Days FREE Trial $229M 1758.3x -39.7x
FNCH Unlock Forecast - 30 Days FREE Trial $19M -0.1x 1.4x
FTII Unlock Forecast - 30 Days FREE Trial $3M x -0.7x
FTIIU Unlock Forecast - 30 Days FREE Trial $-26M x -0.8x
GILD Unlock Forecast - 30 Days FREE Trial $147102M 23.8x 7.5x
GLUE Unlock Forecast - 30 Days FREE Trial $805M 23.0x 3.0x
GNTA Unlock Forecast - 30 Days FREE Trial $58M x 4.7x
GPLB Unlock Forecast - 30 Days FREE Trial $1M x x
HALO Unlock Forecast - 30 Days FREE Trial $7602M 14.0x 22.9x
HLVX Unlock Forecast - 30 Days FREE Trial $105M -0.6x 0.7x
HUMA Unlock Forecast - 30 Days FREE Trial $253M -3.3x 62.5x
IBRX Unlock Forecast - 30 Days FREE Trial $2216M -3.6x -4.1x
IKT Unlock Forecast - 30 Days FREE Trial $115M -1.0x 1.4x
IMCR Unlock Forecast - 30 Days FREE Trial $1655M x 4.3x
IMVT Unlock Forecast - 30 Days FREE Trial $3704M -14.5x 6.1x
INBX Unlock Forecast - 30 Days FREE Trial $1131M -6.8x 16.5x
INKT Unlock Forecast - 30 Days FREE Trial $56M -1.5x -1.4x
INMB Unlock Forecast - 30 Days FREE Trial $49M -2.5x 1.7x
INTS Unlock Forecast - 30 Days FREE Trial $7M -2.2x 3.1x
IOVA Unlock Forecast - 30 Days FREE Trial $694M -4.5x 1.0x
IPSC Unlock Forecast - 30 Days FREE Trial $50M -0.7x 0.2x
IVVD Unlock Forecast - 30 Days FREE Trial $225M -0.4x 5.3x
JSPR Unlock Forecast - 30 Days FREE Trial $40M -3.2x 1.7x
KLRS Unlock Forecast - 30 Days FREE Trial $87M x 1.6x
KLTO Unlock Forecast - 30 Days FREE Trial $32M x 3.0x
KOD Unlock Forecast - 30 Days FREE Trial $1054M -2.5x 15.0x
KRYS Unlock Forecast - 30 Days FREE Trial $5470M 36.7x 5.3x
KYMR Unlock Forecast - 30 Days FREE Trial $4335M -17.8x 4.5x
KYTX Unlock Forecast - 30 Days FREE Trial $292M x 1.6x
LADX Unlock Forecast - 30 Days FREE Trial $0M x x
LCTX Unlock Forecast - 30 Days FREE Trial $419M -4.7x 8.7x
LENZ Unlock Forecast - 30 Days FREE Trial $873M -6.7x 4.2x
LIMN Unlock Forecast - 30 Days FREE Trial $0M x x
LXEO Unlock Forecast - 30 Days FREE Trial $509M -0.4x 3.7x
MAZE Unlock Forecast - 30 Days FREE Trial $1408M x 5.4x
MGTX Unlock Forecast - 30 Days FREE Trial $716M -3.4x 241.9x
MGX Unlock Forecast - 30 Days FREE Trial $108M x 0.6x
MRNA Unlock Forecast - 30 Days FREE Trial $10946M -3.2x 1.2x
NBIX Unlock Forecast - 30 Days FREE Trial $13763M 40.8x 4.6x
NMRA Unlock Forecast - 30 Days FREE Trial $473M -3.9x 2.6x
NVAX Unlock Forecast - 30 Days FREE Trial $1348M 3.2x 35.8x
OCGN Unlock Forecast - 30 Days FREE Trial $432M -4.3x 141.7x
PASG Unlock Forecast - 30 Days FREE Trial $26M -0.6x 0.7x
PCVX Unlock Forecast - 30 Days FREE Trial $5809M -20.4x 1.9x
PHGE Unlock Forecast - 30 Days FREE Trial $15M 1.5x 0.8x
PLUR Unlock Forecast - 30 Days FREE Trial $34M -1.4x -9.1x
PLX Unlock Forecast - 30 Days FREE Trial $144M 23.0x 2.9x
PRME Unlock Forecast - 30 Days FREE Trial $603M -1.5x 9.9x
PROK Unlock Forecast - 30 Days FREE Trial $198M x 0.0x
QGEN Unlock Forecast - 30 Days FREE Trial $10411M x 2.9x
QNCX Unlock Forecast - 30 Days FREE Trial $100M -1.7x 8.5x
REPL Unlock Forecast - 30 Days FREE Trial $809M -3.8x 2.4x
RGEN Unlock Forecast - 30 Days FREE Trial $8133M 8219.1x 3.9x
RGNX Unlock Forecast - 30 Days FREE Trial $657M -1.8x 3.1x
RLAY Unlock Forecast - 30 Days FREE Trial $1242M -2.0x 1.9x
RVMD Unlock Forecast - 30 Days FREE Trial $11003M -11.1x 5.9x
RXRX Unlock Forecast - 30 Days FREE Trial $2541M -4.7x 2.8x
SANA Unlock Forecast - 30 Days FREE Trial $1203M -2.1x 9.8x
SCLX Unlock Forecast - 30 Days FREE Trial $90M -0.4x -0.3x
SCNI Unlock Forecast - 30 Days FREE Trial $8479M -287.8x 1079.1x
SGMO Unlock Forecast - 30 Days FREE Trial $137M -1.6x 7.0x
SLDB Unlock Forecast - 30 Days FREE Trial $417M -0.9x 1.6x
SLXN Unlock Forecast - 30 Days FREE Trial $2M x 17.0x
SRRK Unlock Forecast - 30 Days FREE Trial $2820M -18.5x 12.1x
SRZN Unlock Forecast - 30 Days FREE Trial $116M -0.5x 2.5x
STRO Unlock Forecast - 30 Days FREE Trial $86M -1.0x -2.5x
TARA Unlock Forecast - 30 Days FREE Trial $212M -2.1x 1.5x
TARS Unlock Forecast - 30 Days FREE Trial $2850M -12.4x 8.6x
TCBPY Unlock Forecast - 30 Days FREE Trial $13M x 11.8x
TCRX Unlock Forecast - 30 Days FREE Trial $300M -4.6x 1.7x
TECX Unlock Forecast - 30 Days FREE Trial $329M -8.9x 1.2x
TNYA Unlock Forecast - 30 Days FREE Trial $247M -2.5x 2.5x
TRML Unlock Forecast - 30 Days FREE Trial $1233M -3.5x 4.8x
TSHA Unlock Forecast - 30 Days FREE Trial $1392M -3.0x 5.6x
TVGN Unlock Forecast - 30 Days FREE Trial $136M x -29.3x
TWST Unlock Forecast - 30 Days FREE Trial $1938M -12.6x 4.1x
VACH Unlock Forecast - 30 Days FREE Trial $66M x 0.0x
VACHU Unlock Forecast - 30 Days FREE Trial $67M x 0.0x
VCEL Unlock Forecast - 30 Days FREE Trial $1759M 257.8x 5.7x
VIR Unlock Forecast - 30 Days FREE Trial $841M -2.0x 0.9x
VOR Unlock Forecast - 30 Days FREE Trial $3141M -0.6x 3.9x
VXRT Unlock Forecast - 30 Days FREE Trial $82M -0.9x 2.5x
VYGR Unlock Forecast - 30 Days FREE Trial $258M 570.6x 1.1x
ZIVO Unlock Forecast - 30 Days FREE Trial $48M -31.3x -2.0x

Frequently Asked Questions - Candel Therapeutics, Inc. Stock Forecast

How accurate are Candel Therapeutics, Inc. stock predictions?

Our AI model shows a 42% Spearman correlation coefficient for CADL predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Candel Therapeutics, Inc. stock price forecasts?

Our analysis considers Candel Therapeutics, Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Candel Therapeutics, Inc. a good investment in 2025?

Based on our AI analysis, Candel Therapeutics, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Candel Therapeutics, Inc. forecasts updated?

Candel Therapeutics, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced Candel Therapeutics, Inc. Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Candel Therapeutics, Inc. stock.

🎯 Get Premium Analysis 📊 Explore More Stocks

My Portfolio

Investment Dashboard

Loading your portfolio...